Microba Life Sciences

Executive Summary

Microba Life Sciences is a Melbourne-based diagnostics company offering the first clinical-grade gut microbiome test that integrates shotgun metagenomics, targeted PCR, and ELISA-based inflammatory markers into a single actionable report. Backed by a proprietary database of over 1,500 peer-reviewed studies, Microba’s platform provides personalized insights for diet, lifestyle, and supplementation, targeting gastrointestinal, metabolic, and immunological conditions. Since its founding in 2020, the company has raised $30 million and reached commercial stage with an employee base of 50–200, positioning itself as a leader in the precision microbiome testing market. The global microbiome diagnostics market is expanding rapidly, driven by increasing awareness of the gut-brain axis and personalized medicine. Microba differentiates through its comprehensive, evidence-backed approach and focus on clinical validation. Key growth catalysts include expanding into the U.S. market, securing FDA clearance for its tests, and forming strategic partnerships with pharmaceutical companies for drug development and companion diagnostics. With its robust technology and scalable platform, Microba is well-positioned to capture significant market share in both consumer and clinical segments.

Upcoming Catalysts (preview)

• Q2 2027FDA 510(k) clearance for flagship gut microbiome test60% success
• Q4 2026Strategic partnership with a major pharmaceutical company for microbiome-based drug development65% success
• Q3 2026Series B funding round to support U.S. expansion and R&D80% success